Multiparametric flow cytometric analysis of interpatient variation in STAT1 phosphorylation following interferon alfa immunotherapy

Journal of the National Cancer Institute

Volumn 96, Issue 17, 2004, Pages 1331-1342

  Lesinski, Gregory B ^a   Kondadasula, Sri Vidya ^a   Crespin, Tim ^b   Shen, Lei ^a   Kendra, Kari ^a   Walker, Michael ^a   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Primetrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PHOSPHATE; SODIUM CHLORIDE; STAT1 PROTEIN; STAT2 PROTEIN; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; STAT1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; DONOR; DOSE RESPONSE; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION REGULATION; HOST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTERFERON ALFA-2B; KILLER CELLS, NATURAL; MELANOMA; MONOCYTES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANS-ACTIVATORS;

EID: 4444226259     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh252     Document Type: Article

References (41)

1. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 1998;12:877-902.
2. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20: 1818-25.
3. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
4. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, et al. The anti-tumor effects of interferon-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003;112:170-80.
5. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182:323-31.
6. Navarro S, Colamonici OR, Llombart-Bosch A. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod Pathol 1996;9:150-6.
7. von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C, et al. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. Melanoma Res 1993;3:173-80.
8. Haque SJ, Williams BR. Signal transduction in the interferon system. Semin Oncol 1998;25:14-22.
9. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
10. Levy DE, Kessler DS, Pine R, Reich N, Darnell JE Jr. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev 1988;2:383-93.
11. Meraro D, Gleit-Kielmanowicz M, Hauser H, Levi BZ. IFN-stimulated gene 15 is synergistically activated through interactions between the myelocyte/lymphocyte-specific transcription factors, PU.1, IFN regulatory factor-8/IFN consensus sequence binding protein, and IFN regulatory factor-4: characterization of a new subtype of IFN-stimulated response element. J Immunol 2002;168:6224-31.
12. Hatina VJ, Kralova J, Jansa P. Identification of an intragenic interferon-stimulated response element sequence of the mouse class I major histocompatibility complex H-2Kb gene. Exp Clin Immunogenet 1996;13:55-60.
13. Ohmori Y, Hamilton TA. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 1995;154:5235-44.
14. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983.
15. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999;90:425-30.
16. Ji S, Frank SJ, Messina JL. Growth hormone-induced differential desensitization of STAT5, ERK, and Akt phosphorylation. J Biol Chem 2002;277: 28384-93.
17. Sadowski HB, Shuai K, Darnell JE, Jr., Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993;261:1739-44.
18. Carson WE. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Cancer Res 1998;4:2219-28.
19. Vegh Z, Mazumder A. Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol Immunother 2003;52:67-79.
20. Zar JH. Biostatistical analysis. 4th ed. Upper Saddle River (NJ): Prentice-Hall; 1999. p. 136-9.
21. Moschella F, Bisikirska B, Maffei A, Papadopoulos KP, Skerrett D, Liu Z, et al. Gene expression profiling and functiorial activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin Cancer Res 2003;9:2022-31.
22. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-71.
23. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-in filtrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995;61:765-72.
24. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-74.
25. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1: 1327-35.
26. Shah I, Band J, Samson M, Young J, Robinson R, Bailey B, et al. Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. Am J Hematol 1984;17:363-71.
27. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-8.
28. Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin Immunol 2001;100: 270-6.
29. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002;20:155-62.
30. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003;100:1896-901.
31. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993;53:1380-7.
32. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 1988;42:659-66.
33. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109-19.
34. Sato M, Goto S, Kaneko R, Ito M, Sato S, Takeuchi S. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 1998;18:3951-5.
35. IjIand SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999;9:445-50.
36. Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, Fabbri P, et al. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001; 11:395-9.
37. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67-8.
38. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 2000;6:3895-903.
39. Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA. Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res 1996;6:191-201.
40. Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res 1999;9:261-72.
41. Carson WE, Sundaram P, Nadella P, Anghelina M, Dierksbeide S, Dierksheide J, et al. A phase I trial of interleukin-12 and interferon-alpha [abstract 2242]. Proc ASCO 2000;19:569a.